Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Estramustine, Etoposide, and Paclitaxel in Hormone-Responsive Prostate Cancer
NCT00151060Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 1998
- Primary completion
- Nov 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estramustine, etoposide and paclitaxel in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Time to treatment failure. Started Dec 1998; status: completed.
02
Drugs
estramustineetoposidepaclitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00151060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151060.